Latest Oncology Stories
A novel gene variant found in human and animal tissue may be a promising treatment for cancer, including breast and brain cancer, according to scientists from the Icahn School of Medicine at Mount Sinai. New York, NY (PRWEB) June 06, 2013 A novel gene variant found in human and animal tissue may be a promising treatment for cancer, including breast and brain cancer, according to scientists from the Icahn School of Medicine at Mount Sinai. The variant, called PTEN-long, may contribute to a...
Partnership Seeks to Accelerate Development of Innovative Therapies WHITE PLAINS, N.Y., June 6, 2013 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) today joined the Dana-Farber Cancer Institute in Boston to establish a network of sites for clinical trial testing of innovative blood cancer therapies in community oncology settings across the country. This groundbreaking Blood Cancer Research Partnership (BCRP) will bring clinical trials closer to where patients live...
George Mason University Funded by volleyball tournaments, a new study released this week shows success in pinpointing individualized treatment for women with metastatic breast cancer, according to George Mason University researchers. The Side-Out Foundation’s pilot study is part of a cutting-edge approach to personalized medicine that looks beyond genomic analysis alone to combine it with what some say is the next frontier in targeted therapy: proteomics. The pilot study is the...
Veran's innovative technology used for the potential early diagnosis of cancer included in ACCP guidelines for establishing the diagnosis of lung cancer ST. LOUIS, June 6, 2013 /PRNewswire/ -- Veran Medical Technologies, the electromagnetic navigation experts and original creator of Always-On Tip Tracked(®) instruments, announced today the launch of SPiNDrive(®) 2.0 software. Veran's SPiNDrive 2.0 is an electromagnetic navigation platform that allows physicians to biopsy solitary...
Fifth Validation Study Demonstrating Ability to Identify Tumor Origin in Patients with Cancer of Unknown or Uncertain Primary Shows 92% Accuracy, Highest Published Level to Date PHILADELPHIA and REHOVOT, Israel, June 6, 2013 /PRNewswire/ -- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that a manuscript reporting data validating the clinical utility of the Rosetta Cancer Origin Test((TM)) (formerly...
NEW YORK, June 6, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. Today, Wall Street Reports announced new research reports highlighting Clovis Oncology Inc. (NASDAQ: CLVS), MannKind Corporation (NASDAQ: MNKD), TESARO Inc. (NASDAQ: TSRO), Peregrine Pharmaceuticals (NASDAQ: PPHM), and Vanda Pharmaceuticals Inc. (NASDAQ: VNDA). Today's readers may access these reports free of charge - including full price targets,...
WHITE PLAINS, N.Y., June 5, 2013 /PRNewswire/ -- Today's U.S. Food and Drug Administration (FDA) approval of lenalidomide (Revlimid®) to treat patients with mantle cell lymphoma (MCL) is encouraging news for these patients. "Despite advances in treatment, most mantle cell lymphoma patients relapse over time. So, lenalidomide is a welcome effective treatment option for these patients," said Clare Karten, senior director of mission education for The Leukemia & Lymphoma Society...
SPRINGFIELD, Ill., June 5, 2013 /PRNewswire-USNewswire/ -- Blue Cross and Blue Shield of Illinois (BCBSIL) is proud to be the In the Pink Sponsor of the "Play for the Cure" golf outing this Saturday, June 8(th), at Brookhills Golf Club in Springfield. The fundraiser features golfing, lunch, awards and a cocktail party, but with a twist - it's a women-only event that will be staffed only by men! "Play for the Cure" benefits the local affiliate of Susan G. Komen for the Cure(TM),...
June 5 - June 25 campaign to help in the fight against blood cancer SAN BERNARDINO, Calif., June 5, 2013 /PRNewswire/ -- The Leukemia & Lymphoma Society is teaming up once again with Stater Bros. Charities for the sixth year of The Leukemia & Lymphoma Society's "Light The Night" fundraising campaign to raise awareness and funds for Leukemia, Hodgkin and Non-Hodgkin Lymphoma, Myeloma and Myelodysplastic Syndromes. (Logo:...
Surveyed U.S. Payers Are Most Receptive to Therapies Offering a Significant Median Overall Survival Benefit over Currently Available Therapies, According to a New Report from Decision Resources BURLINGTON, Mass., June 5, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that symptom control and quality of life is one of the factors the most influences surveyed U.S. and European oncologists'...
